Wells Fargo lowered the firm’s price target on Editas Medicine (EDIT) to $9 from $27 and keeps an Equal Weight rating on the shares. With ...

Editas, one of the oldest CRISPR-focused biotechs, is pivoting again — to a sickle cell treatment that requires editing a ...

In a report released yesterday, Terence Flynn from Morgan Stanley maintained a Hold rating on Editas Medicine (EDIT – Research Report), ...

Shares of Editas Medicine EDIT plunged 12.5% on Tuesday after announcing that it is seeking a global partner to advance its ...

Editas Medicine is pushing its in vivo gene therapy strategy to the top of its agenda, boasting proof-of-concept data and ...

AvenCell Therapeutics announced that it raised $115 million in a Series B round. The company is developing CAR-T therapies ...

The gene editing company will focus on “in vivo” medicines, while seeking to license out or find a development partner for ...

Editas is partnering its CRISPR platform with Genevant’s LNP technology to develop novel gene editing medicines in a deal ...

Editas Medicine, Inc. EDIT announced that it has entered into a collaboration and nonexclusive license agreement with ...

Editas Medicine, Inc. ( NASDAQ: EDIT) Strategic Update Conference Call October 22, 2024 8:00 AM ET ...

Given the large stake in the stock by institutions, Editas Medicine's stock price might be vulnerable to their trading ...

CAMBRIDGE, Mass. and VANCOUVER, British Columbia and BASEL, Switzerland, Oct. 21, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: EDIT), a ...